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Abstract 
 
Many advances have been made in the characterisation of primary liver tumours in humans, in 
particular relating to the identiﬁcation and role of hepatic progenitor cells, resulting in a new 
classiﬁcation. The aim of the present study was to investigate the presence and relative frequency of 
morphological types of canine primary hepatic neoplasms and to determine whether a classiﬁcation 
similar to the human scheme can be applied to these canine neoplasms. Canine primary liver 
tumours (n = 106) were examined histologically and with the immunohistochemical markers keratin 
19, HepPar-1, epithelial membrane antigen/mucin-1, CD10, neuron-speciﬁc enolase and 
chromogranin-A. Eleven nodular hyperplasias and 82 tumours of hepatocellular origin were 
diagnosed. The latter were subdivided in hepatocellular tumours with 0–5% positivity for K19 (n = 
62), which were well differentiated and had no evidence of metastasis, tumours with >5% positivity 
for K19 (n = 17), which were poorly differentiated and had intra- hepatic and/or distant metastasis, 
and a scirrhous subgroup (n = 3) with an intermediate position with regard to K19 staining and 
malignancy. Ten cholangiocellular tumours (nine cholangiocellular carcinomas and one 
cholangiolocarcinoma) were diagnosed and all had intrahepatic and/or distant metastases. Three 
neuroendocrine carcinomas were also diagnosed. Histopathological and immunohistochemical 
examination of canine primary hepatic neoplasms can differentiate hepatocellular, cholangiocellular 
and neuroendocrine tumours, in accordance with the most recent human classiﬁcation system. 
  
Introduction 
 
Primary liver tumours in dogs are relatively rare, representing 0.6–1.5% of all tumours in dogs 
(Patnaik et al., 1980, 1981). No predisposing factors are known and, in almost all cases, no additional 
primary liver pathology is present (Hammer and Sikkema, 1995; Watson, 2005). Currently, canine 
neoplasms are classiﬁed as hepatocellular adenomas and carcinomas, cholangiocellular adenomas 
and carcinomas, mixed hepatocellular and cholangiocellular carcinomas, and hepatic carcinoids 
(Cullen and Popp, 2002; Charles et al., 2006; Stalker and Hayes, 2007); to date, hepatoblastomas 
have not been recognised in the dog (Charles et al., 2006). 
Over the past decade, many advances have been made in the characterisation of primary liver 
tumours in humans, in particular relating to the identiﬁcation and signiﬁcance of hepatic progenitor 
cells (HPCs) (Allison and Lovell, 2005; Libbrecht, 2006; Roskams, 2006). HPCs are multipotent cells, 
located within the canals of Hering, with the capacity for self-renewal and differentiation into mature 
hepatocytes and cholangiocytes (Libbrecht and Roskams, 2002; Turner et al., 2011; Boulter et al., 
2012). In primary hepatocellular tumours of dogs, tumours with HPC characteristics are poorly 
differentiated and aggressive (van Sprundel et al., 2010). Recent studies of the role of HPCs in the 
development and differentiation of intrahepatic cholangiocellular tumours in humans have resulted 
in a new histomorphological and immunohistochemical classiﬁcation of primary liver tumours in 
humans, taking into account their aggressiveness and prognosis (Komuta et al., 2008, 2012). 
In humans, primary liver tumours may arise from mature hepatocytes or cholangiocytes, 
representing hepatocellular and cholangiocellular adenomas and carcinomas, respectively (Fig. 1). 
Hepatic tumours may also arise from HPCs; such neoplasms exhibit varying degrees of 
differentiation, sometimes with overlapping morphological features, e.g. cholangiolocarcinomas 
(Komuta et al., 2008, 2012; Yeh, 2010). Cholangiolocarcinomas are thought to originate from the 
canals of Hering and have hepatocellular, ductular and cholangiocellular characteristics (Komuta et 
al., 2008, 2012; Seok et al., 2012). 
 
 
Fig. 1. Proposed origin and classiﬁcation of primary liver tumours in humans. Primary liver tumours may arise from mature 
hepatocytes or cholangiocytes, representing the classic hepatocellular and cholangiocellular adenomas and carcinomas. 
They may also arise from hepatic progenitor cells showing varying degrees of differentiation and develop various and 
sometimes overlapping morphological features, such as cholangiolocarcinomas. HPC, hepatic progenitor cell; HCC, 
hepatocellular carcinoma; CC, cholangiocellular carcinoma; CLC, cholangiolocarcinoma; K19, keratin 19. 
Primary hepatic neoplasms in dogs can be classiﬁed and differentiated using immunohistochemical 
stains for markers representative of hepatocytic and cholangiocytic lineages (Lau et al., 2002; 
Morrison et al., 2002; Libbrecht, 2006; van Sprundel et al., 2010; Al-Muhannadi et al., 2011). The aim 
of the present study was to investigate the occurrence and relative frequency of various 
morphological types of primary hepatic neoplasms in the dog and to determine whether a 
classiﬁcation similar to the human scheme can be applied to canine hepatic neoplasms.  
Materials and methods 
Samples 
 
Formalin-ﬁxed parafﬁn-embedded material from primary liver tumours of 106 dogs was available 
from the archives of the Department of Pathobiology, Utrecht University (n = 18), Valuepath, 
Laboratory for Veterinary Pathology, Hoensbroek, The Netherlands (n = 28), the Institute of 
Veterinary Pathology, University of Zürich, Switzerland (n = 46), and the Institute of Veterinary 
Pathology, Free University Berlin, Germany (n = 14). All material was derived from clinical cases and 
had been submitted for individual diagnostic purposes; no tissue was collected speciﬁcally for the 
purpose of the present study. Formalin-ﬁxed parafﬁn-embedded samples from the livers of healthy 
dogs, as well as a sample from a dog with fulminant hepatitis and reactive ductular proliferation, 
were available from the Department of Clinical Sciences of Companion Animals, Utrecht University. 
Grading and staging 
 
Histological grading and staging of the tumours was performed as described by van Sprundel et al. 
(2010). The parameters scored from 0 to 3 for grading comprised cell and nuclear pleomorphism, 
presence or absence of multinucleated tumour cells and mitotic activity. Three stages were based on 
histopathology, anamnestic data (ultrasonography and surgery reports, including follow-up data 
from referring veterinarians and/or owners) and postmortem pathology reports: (1) stage 0: 
Macroscopically only one tumour process was present in the liver and/or microscopically the tumour 
was well circumscribed or encapsulated; there was no evidence of intrahepatic and/or extrahepatic 
metastases; (2) stage 1: Microscopically the tumour had spread beyond the original (primary) site to 
the adjacent tissue, there was evidence of intravascular spread or the presence of microsatellites 
and/or multiple tumour processes were present in the liver macroscopically; and (3) stage 2: The 
tumour had spread from the primary site to the regional lymph nodes and/or other organs (distant 
metastasis). 
 
  
Immunohistochemistry 
 
Immunohistochemistry was performed for keratin 19 (K19), HepPar-1, epithelial membrane 
antigen/mucin-1 (EMA/MUC-1), CD10,  neuron-speciﬁc enolase (NSE), and chromogranin-A (Cg-A) 
(Table 1). Negative controls were performed by replacing the primary antibody with washing buffer. 
Adrenal glands served as a positive control for NSE and Cg-A. 
Results 
 
Bile ducts in the liver from a healthy dog had strong cytoplasmic staining for K19 (Fig. 2A) and 
EMA/MUC-1 (Fig. 2D). There was moderate to marked cytoplasmic staining of hepatocytes for 
HepPar-1,  probably depending on  glycogen content (Fig.  2C). CD10 exhibited mild to marked 
canalicular staining and apical membranous staining of the smallest bile ducts (Fig. 2E); activated 
hepatic stellate cells exhibited positive immunostaining, whereas large bile ducts were negative (Fig. 
2F). Strong positive staining for K19 was evident in reactive HPCs in areas of ductular proliferation in 
the canine liver with hepatitis (Fig. 2B), whereas these cells were negative for NSE and Cg-A. In the 
healthy liver, rare NSE positive epithelial cells were present in the epithelial lining of a larger bile 
duct; Cg-A was always negative. 
 
Table 1 
Antibody characteristics and experimental procedures for immunohistochemistry. 
 
Antibody Manufacture
r 
Type Clone Antigen retrieval Dilution Wash buffer Incubation 
K 19 Novocastra Mouse 
mAb 
B170 Proteinase K 1:100 TBS 1 h RT 
HepPar-1 Dakocytomati
on 
Mouse 
mAb 
OCH1E5 TBS/EDTA 1:50 PBS Overnight 
       4 C 
CD10 Novocastra Mouse 
mAb 
56C6 Epitope retrieval solution 2 Ready to use Bond wash solution 10x concentrate 0.5 h RT 
EMA/MUC- Biosciences Rab it pAb LS-C30532 TBS/EDTA 1:700 PBS 24 h 4 C 
1        
NSE Dakocytomati
on 
Mouse 
mAb 
BBS/NC/VI- Citrate 1:400 PBS Overnight 
   H14    4 C 
Cg-A MP Products Rabbit mAb 20086 SP-1 No antigen retrieval 1:800 PBS Overnight 
       4 C 
Cg-A, chromogranin-A; EDTA, ethylene diamine tetraacetic acid; EMA/MUC-1, epithelial membrane antigen/mucin-1; K19, keratin 19; mAb, 
monoclonal antibody; NSE, neuron-speciﬁc enolase; O/N, overnight; PBS, phosphate-buffered saline; pAb, polyclonal antibody; Prot K, proteinase K; RT, 
room temperature; TBS, Tris-buffered saline. 
 
 
 Fig. 2. Immunohistochemical staining of non-tumorous liver tissue. (A) K19, normal liver, portal area with positive staining 
bile duct and ductule; (B) K19, acute fulminant hepatitis with positive staining of reactive ductular proliferation; (C) HepPar-
1, normal liver, marked staining of hepatic cords, portal area negative; (D) EMA/MUC-1, normal liver, positive staining bile 
duct; (E) CD10, normal liver, moderate positive staining of canaliculi, apical staining of smallest bile duct (arrow) and 
positive staining of hepatic stellate cells; (F) CD10, normal liver, marked canalicular staining, negative staining of larger bile 
ducts in portal area 
 
On histopathological and immunohistochemical examination, the 106 primary liver tumours were 
classiﬁed as 11 nodular hyperplasias (10%), 82 hepatocellular tumours (77%), 10 cholangiocellular 
tumours (9%) and three hepatic neuroendocrine tumours (3%). There was no apparent sex or breed 
predisposition for a particular tumour type. The age of the dogs ranged from 6 to 18 years; younger 
dogs mostly were larger or giant breeds, but no statistical analysis was undertaken. In four dogs with 
cholangiocellular tumours, the livers also had ﬁbrous areas with conglomerates of irregularly formed 
cystic / dilated bile ducts, consistent with adult-type congenital cystic liver disease (van den Ingh et 
al., 2006), whereas in the other dogs the non-neoplastic liver parenchyma was histologically normal. 
  
Nodular hyperplasia (n = 11) 
 
Histologically, hyperplastic nodules contained double layered cords of well-differentiated 
hepatocytes with slight compression of the surrounding parenchyma (Fig. 3A); characteristically, 
portal areas were present within the hyperplastic nodules (Fig. 3D). Hepatocytes had a uniform and 
normal appearance, and there 
was  no mitotic activity (grade 0). All hyperplastic nodules had moderate to marked cytoplasmic 
staining for HepPar-1 (Fig. 3B) and mild to marked canalicular staining for CD10 (Fig. 3C), but were 
negative for K19 (Fig. 3D), EMA/MUC-1, NSE and Cg-A. 
 
Hepatocellular tumours (n = 82) 
 
Hepatocellular tumours were divided in three groups on the basis of histopathological features and 
immunohistochemical staining for K19 (Table 2). 
Hepatocellular tumours with 0–5% cells positive for K19 (n = 62) 
 
Fifty-seven tumours of this type were received as surgical specimens and ﬁve were obtained at 
postmortem examination. On histopathological examination, these tumours were well demarcated 
and encapsulated, and consisted of broad trabeculae of well differentiated hepatocytes (Fig. 4A) 
separated by ﬁne ﬁbrovascular stroma and sometimes widely dilated sinusoids and cavernous blood-
ﬁlled spaces; regularly, haemorrhagic and/or necrotic areas were present. In one case with medium-
sized tumour cells, acinar conﬁgurations were present in addition to trabecular areas. The 
hepatocytes were well differentiated and had no or limited cellular pleomorphism, with no or rare 
mitotic ﬁgures (grade 0–2); they regularly showed areas with swollen glycogen-rich hepatocytes or 
hepatocellular steatosis and sometimes contained foci of extramedullary haematopoiesis. There was  
no evidence of inﬁltrative growth, intrahepatic vascular invasion or metastases. The tumours had 
moderate to marked positive cytoplasmic staining for HepPar-1 (Fig. 4B) and minimal to marked 
canalicular staining for CD10 (Fig.  4C).  Staining for  K19  was  negative in  most tumours (Fig. 4D); 
there were 1–5% positive tumour cells with cytoplasmic or membranous staining in 16/62 (25.8%) 
cases (Fig. 4E). EMA/ MUC-1 staining was negative in all tumours (Fig. 4F). Ten tumours were positive 
(<20% of cells) for NSE and one of these tumours was also positive for Cg-A (<5%). 
 
 Fig. 3. Nodular hyperplasia. (A) HE, nodular hyperplasia with bilayered hepatic cords; compressed pre-existent liver tissue 
(lower right); (B) HepPar-1, positive staining of hepatocytes in both nodular hyperplasia and compressed pre-existent tissue 
(lower right); (C) CD10, mild canalicular staining and positive hepatic stellate cells; (D) K19, positive pre-existent bile duct 
within the negative staining nodular hyperplasia, compressed negative pre-existent parenchyma (upper right). 
 
Table 2 
Histological classiﬁcation and immunohistochemistry of canine hepatocellular tumours. 
 
 K19 Grading Staging HepPar-1 NSE Cg-A CD10 EMA/MUC-1 
HCT 0–5% K19+ 0% (n = 46) 0 (n = 10) 0 (n = 62) 100% (n = 54) 0% (n = 52) 0% (n = 61) 30–100% 0% (n = 62) 
 1–5% (n = 16) 1 (n = 35) 
2 (n = 17) 
 60–90% (n = 8) 5–20% (n = 10) 5% (n = 1) (n = 62)  
HCT >5% K19+ 40–100% (n = 17) 1   3) 
2 (n = 6) 
3 (n = 8) 
1 (n = 4) 
2 (n = 13) 
0% (n = 15) 
5–20% (n = 2) 
0% (n = 15) 
20–40% (n = 2) 
0% (n = 16) 
5% (n = 1) 
0% (n = 17) 0% (n = 17) 
sHCT Ductular 100% 0 (n = 1) 0 (n = 2) Ductular 0% Ductular 100% 0% (n = 3) Ductular 0% 0% (n = 3) 
 Trabecular 0% Solid 
100% (n = 3) 
1 (n = 2) 1 (n = 1) Trabecular 100% Solid 
0% (n = 3) 
Trabecular 0% Solid 
80% (n = 3) 
 Trabecular 50% Solid 
5% (n = 3) 
 
Cg-A, chromogranin-A; EMA/MUC-1, epithelial membrane antigen/mucin-1; HCT, hepatocellular tumour; K19, keratin 19; NSE, neuron-speciﬁc 
enolase; sHCT, scirrhous hepatocellular tumour. 
  
Hepatocellular tumours with >5% cells positive for K19 (n = 17) 
 
Twelve tumours of this type were obtained at postmortem examination and ﬁve were received as 
surgical specimens. Histologically, these tumours formed irregular trabeculae and markedly 
inﬁltrated the surrounding parenchyma. The cells were small compared to normal hepatocytes and 
were poorly differentiated, with marked cellular and nuclear pleomorphism, and many mitotic 
ﬁgures (up to 10 per high power ﬁeld) (Fig. 5A). All exhibited lymphatic  and vascular invasion in  
portal tracts (Fig.  5B)  and had intrahepatic and/or distant metastases. The K19 positive cells in these 
tumours showed strong cytoplasmic staining (Fig. 5C). Most of the tumours were negative for 
HepPar-1 (Fig. 5D); in two cases, 5% and 20% of tumour cells were positive for this marker. CD10 (Fig. 
5E) and EMA/MUC-1 were negative in all tumours. In two cases, 20% and 40% of the tumour cells 
were positive for NSE. In one case, 5% of tumour cells were positive for Cg-A. 
 
Scirrhous hepatocellular tumours with K19 positive ductular structures (n = 3) 
 
All of these tumours were received as surgical specimens. They contained areas with trabecular 
structures of well-differentiated hepatocytes (grade 0) and multifocal areas with a ﬁbrous stromal 
component and ductular growth patterns (grade 1), whereby the trabecular areas were continuous 
with the ductular structures (Fig. 6A). The trabecular areas were strongly positive for HepPar-1 and 
moderately positive for  CD10,  but negative for  K19 (Fig. 6B). The ductular structures in areas of 
ﬁbrosis were positive for K19 (Fig. 6B) and NSE (Fig. 6C), but negative for HepPar-1 and CD10. The 
tumours were negative for EMA/MUC-1 and Cg-A. In two tumours, the ductular/ﬁbrotic areas were 
well-circumscribed and were present within the well-differentiated trabecular component. In one 
tumour, the ductular component showed inﬁltrative growth, with ductular and solid areas in ﬁbrous 
connective tissue adjacent to a large portal area (Fig. 6D). In this solid area, there was diffuse 
positivity for K19 (Fig. 6E) and irregular positivity for CD10 (Fig. 6F). 
 
 
 Fig. 4. Hepatocellular tumours 0–5% K19 positive. (A) HE, encapsulated tumour with moderate cellular pleiomorphism; (B) 
HepPar-1, marked cytoplasmic staining of neoplastic tissue; (C) CD10, marked canalicular staining in neoplastic tissue; (D) 
K19, neoplastic tissue negative, biliary proliferation in surrounding capsule positive; (E) K19, cells with either diffuse 
cytoplamic or membranous (arrow) staining in a less than 5% positive tumour; (F) EMA/MUC-1, negative staining of 
neoplastic tissue. 
 
Cholangiocellular tumours (n = 10) 
 
Ten tumours were classiﬁed as cholangiocellular carcinomas (9%) (Table 3). In most cases, 
cholangiocellular carcinomas were monomorphic, with an acinar, tubular and/or papillary growth 
pattern. In one case, the tumour had the characteristics of human cholangiolocarcinoma, with 
centrally located ductular structures, as well as more peripherally located solid areas with an 
hepatocellular appearance. 
 
  
Cholangiocellular carcinomas (n = 9) 
 
Two tumours were received as surgical specimens and seven were obtained at postmortem 
examination. These tumours had an acinar (Fig. 7A), tubular and/or papillary (Fig. 7B) growth 
pattern. The neoplastic cells were cuboidal to columnar, with a relatively small amount of cytoplasm, 
and had moderate to marked cellular and nuclear pleomorphism, with many mitotic ﬁgures (grade 2–
3). All cholangiocellular tumours had vascular invasion and the presence of intrahepatic and/or 
distant metastases. Positive  immunohistochemical staining for K19 was  evident in 90–100% tumour 
cells in eight cases and 50–60% tumour cells in one case, with a cytoplasmic and, usually, more 
intense membranous staining (Fig. 7C). The tumours were also positive for EMA/MUC-1 (90–100% of 
tumour cells were immunopositive), with an apical membranous and/or diffuse cytoplasmic staining 
pattern (Figs. 7D and E), and were negative for HepPar-1 (Fig. 7F). Two of six tumours were negative 
for CD10 (Fig. 7G); in 4/6 cases, CD10 showed focal apical or cytoplasmic staining in tubulopapillary 
lesions within the tumour (Fig. 7H); there was  insufﬁcient tissue for CD10 immunostaining in three 
case. Two cases were positive for NSE (30% and 100% of tumour cells were immunopositive). Cg-A 
was negative in all cases. 
 
Cholangiolocarcinoma (n = 1) 
 
In one tumour, received as surgical specimen along with the corresponding regional lymph node, 
there was a combination of usually centrally located tubular structures, with or without ﬁbrosis, and 
solid peripheral areas with a more hepatocellular appearance (Figs. 8A and B). The tumour showed 
moderate to marked cellular and nuclear pleomorphism, had a high mitotic activity (grade 3) and was 
classiﬁed as stage 2 because of vascular invasion and intra- hepatic and distant metastasis (Fig. 8C). 
Immunohistochemically, the tumour was negative for HepPar-1. K19 showed 90–100% positive 
staining, whereby the tubular areas showed diffuse cytoplasmic, as well as a more pronounced 
membranous, staining (Figs. 8D and E); the solid areas mainly showed moderate cytoplasmic staining 
for K19 (Fig. 8D). EMA/MUC-1 showed positive apical and/or cytoplasmic staining of tubular 
structures (Fig. 8F), whereas the solid structures were negative (Fig. 8G). CD10 was negative in the 
solid areas (Fig. 8H); apical and some cytoplasmic staining was present in the tubular areas (Fig. 8I) 
and moderate cytoplasmic staining was seen in intravascular metastases (Fig. 8J). There was focal 
cytoplasmic staining for Cg-A in the solid areas of the tumour. Immunostaining for NSE was negative. 
 
 Fig. 5. Hepatocellular tumours with high K19 expression. (A) HE, relatively small tumour cells with abundant mitotic ﬁgures; 
(B) HE, vascular invasion and intrahepatic metastases; (C) K19, marked cytoplasmic staining of tumour cells; (D) HepPar-1, 
negative staining of neoplasm (N); (E) CD10, negative staining of neoplastic cells, some pre-existent hepatic cords with 
canalicular staining are present. 
 
Neuroendocrine carcinomas (n = 3) 
 
One tumour was received as a surgical specimen and two were obtained at postmortem 
examination. Histologically, neuroendocrine carcinomas consisted of medium-sized to large 
columnar cells with abundant cytoplasm and basal nuclei, and had a trabecular and/or rosette 
pattern of growth (Fig. 9A). The tumour cells showed only slight cellular and nuclear pleomorphism, 
the mitotic activity was moderate to high and the tumours were graded as 1. All tumours had 
evidence of intrahepatic metastases (stage 1). K19 staining was negative or <5% of the tumour cells 
were stained (Fig. 9B). HepPar-1 (Fig. 9C), CD10 and EMA/MUC-1 were negative in all cases. All the 
tumours showed >90% positivity for NSE (Fig. 9D). There was >30% immunopositivity for Cg-A in two 
of the tumours (Fig. 9E), whereas the third tumour was negative. 
 
Discussion 
 
In this study, 106 canine primary hepatic neoplasms were classiﬁed into morphologically well-deﬁned 
groups on the basis of histopathological and immunohistochemical examination (Table 4). The 
classiﬁcation system for dogs was based on recent systems for classifying hepatic tumours in  
humans (Komuta et al., 2008, 2012). 
Nodular hyperplasia is a benign hepatocellular proliferation which occurs in many older dogs and can 
be found as single or multiple nodules, often as an incidental ﬁnding during laparotomy or at 
postmortem examination (Watson, 2005; Charles et al., 2006). The relatively low incidence of 
nodular hyperplasia (10%) in this study is likely to be related to the use of archival material, since 
hyperplastic nodules may not be submitted for histopathological evaluation as frequently as 
neoplasms. 
 
Fig. 6. Scirrhous hepatocellular tumours with K19 positive ductular structures. (A) HE, trabecular area with transition to 
ductular structures in ﬁbrotic tissue; (B) K19, positive ductular structures continuous with negative trabecular area; (C) NSE, 
positive ductular structures continuous with negative trabecular area; (D) HE, solid area with malignant transformation and 
inﬁltrative growth; (E) K19, positive staining of solid malignant area; (F) CD10, local positive staining in malignant solid area. 
 
Table 3 
 
 
Hepatocellular tumours were the most common primary hepatic neoplasm in dogs in the present 
study. Nevertheless they appear to occur less frequently in dogs than in humans (Parkin et al., 2001), 
probably because a high proportion of human hepatocellular carcinomas arise from chronic 
infections with hepatitis B or hepatitis C viruses, both of which can lead to chronic inﬂammation and 
cirrhosis. In contrast, most canine hepatocellular tumours arise in otherwise normal appearing livers. 
As in humans, hepatocellular tumours in dogs could be divided into three subgroups, each with 
speciﬁc morphological and immunohistochemical characteristics. Canine tumours that were all or 
mostly K19 negative were most likely to be derived from mature hepatocytes and well circumscribed, 
with a low grade of cellular pleomorphism, and no evidence of inﬁltrative growth or metastases. 
However, a metastatic hepatocellular tumour  (HepPar-1 positive; K19  status unknown) has recently 
been described in a dog (Lamoureux et al., 2012). In contrast, K19 positive canine tumours exhibited 
characteristics of HPCs without further differentiation towards cholangiocytic or hepatocellular 
lineages. These tumours may be derived from HPCs or through dedifferentiation of mature 
hepatocytes (Desmet, 2011). They had a high grade of cellular pleomorphism and exhibited 
inﬁltrative growth, vascular invasion and intrahepatic and/or extrahepatic metastases. This group 
comprised 21% of canine hepatocellular tumours; the frequency of this type of tumour in humans is 
17% (Durnez et al., 2006). 
The third and smallest group of hepatocellular tumours had an intermediate position with respect to 
histomorphology and immunohistochemistry. This group had the characteristics of well-
differentiated hepatocellular tumours, but also  showed multifocal stromal proliferation and 
formation of ductular structures; in 1/3 tumours, inﬁltrative growth suggested malignant 
transformation of the K19 positive structures. A similar morphological entity has been described in 
humans as scirrhous hepatocellular carcinoma, in which the stromal proliferation possibly drives K19 
positive ductular differentiation (Wang et al., 2010). 
 
  
 Fig. 7. Canine cholangiocellular carcinoma. (A) HE, acinar growth pattern; (B) HE, tubulopapillary growth pattern; (C) K19, 
marked positive staining of tubulopapillary area with cytoplasmic and membranous pattern; (D) EMA/MUC-1, diffuse 
cytoplasmic staining of neoplastic cells within acinar growth pattern; (E) EMA/MUC-1, positive cytoplasmic and apical 
staining of tumour cells in tubulopapillary growth pattern; (F) HepPar-1, negative staining of the tumour tissue (N); (G) 
CD10, negative staining of tumour cells within acinar growth pattern; (H) CD10, apical staining of tumour cells in 
tubulopapillary growth pattern. 
  
 Fig. 8. Canine cholangiolocarcinoma. (A) HE, central tubular areas with fibrosis; (B) HE: peripheral solid area; (C) HE, vascular 
invasion; (D) K19, marked staining of central tubular (lower left) and less intense staining of peripheral solid areas (upper 
right); (E) K19, tubular areas with cytoplasmic and more pronounced membranous staining of tumour cells; (F) EMA/MUC-
1, tubular areas with apical and some cytoplasmic staining; (G) EMA/MUC-1, negative staining of solid neoplastic areas, 
slight non-specific staining of pre-existent hepatic cords; (H) CD10, solid peripheral area with negative staining of neoplastic 
cells, some canalicular staining within pre-existent hepatic cords; (I) CD10, tubular areas with positive apical and some 
cytoplasmic staining; (J) CD10, moderate cytoplasmic staining of intravascular metastasis. 
 HepPar-1 K19 CD10 EMA/Muc-1 NSE Cg-A 
Nodular hyperplasia (n = 11) +++ 0 Canalicular + to +++ 0 0 +/- 
(n = 2) 
Hepatocellular adenoma (n = 62) +++ 0–5% Canalicular + to +++ 0 ++ (n = 10) + (n = 1) 
Hepatocellular carcinoma (n = 17) 0 (+) +++ 0 0 + to ++ (n = 2) + (n = 1) 
Scirrhous hepatocellular tumour (n = 3) Ductular 0 trabecular Ductular +++ Ductular 0 trabecular + 0 Ductular +++ 0 
 +++ trabecular 0 to ++  trabecular 0  
Cholangiocellular carcinoma (ductal type) 0 +++ 0 +++ 0 0 
Cholangiocellular carcinoma (ductular 0 +++ + to ++ +++ 0 to ++ (n = 2) 0 
Cholangiolocarcinoma (n = 1) 0 +++ Tubular ++ solid 0 Tubular ++ 0 + 
    solid 0   
Neuroendocrine carcinoma (n = 3) 0 0–5% 0 0 ++ to +++ ++ 
 
 
Fig. 9. Canine hepatic neuroendocrine carcinoma. (A) HE, rosette pattern with ﬁne ﬁbrovascular stroma; (B) K19, focal 
positive staining within tumour; (C) HepPar-1, negative staining of neoplastic tissue (N); (D) NSE, marked cytoplasmic 
staining of neoplastic cells; (E) CgA, moderate cytoplasmic staining of neoplastic cells 
 
Table 4 
Classiﬁcation and immunohistochemical differentiation of the canine primary hepatic neoplasms. 
 
 
 
 
 
 
 
 
(n = 3) 
 
type) (n = 6) 
 
 
 
Cg-A, chromogranin-A; EMA/MUC-1, epithelial membrane antigen/mucin-1; K19, keratin 19; NSE, neuron-speciﬁc enolase. 
 
 
There was a relatively low frequency (9%) of cholangiocellular tumours in our study, possibly because 
dogs have a low incidence of chronic biliary disease. Cholangiocellular neoplasms were associated 
with adult-type congenital cystic disease of the liver (van den Ingh et al., 2006) in 4/10 cases. All nine 
canine cholangiocellular carcinomas were positive for K19 and EMA/MUC-1 and were thought to be 
derived from differentiated mucin-producing cholangiocytes, normally present in larger bile ducts. 
Some of the tumours also showed CD10 positivity, which might suggest a ductular origin. All 
cholangiocellular tumours exhibited inﬁltrative growth, vascular invasion and intrahepatic and/or 
distant metastasis. 
The cholangiolocarcinoma had a different morphology and immunohistochemical pattern in 
comparison with the cholangiocellular carcinomas, with tubular structures (K19, EMA/MUC-1 and 
CD10 positive) and solid hepatocyte-like areas (K19 positive and HepPar-1, EMA/MUC-1 and CD10 
negative). This is suggestive of bidirectional differentiation of HPCs to hepatocytes and 
cholangiocytes (Komuta et al., 2008). No cholangiocellular adenomas were identiﬁed in our case 
series; these tumours are rare and it is  likely  that almost all  of  the cholangiocellular adenomas 
described in the veterinary literature represent adult-type cystic liver disease (Charles et al., 2006). 
The primary hepatic neuroendocrine carcinomas identiﬁed in this study had a similar histological 
appearance to those described by Patnaik et al. (2005). These tumours are rare in the dog and most 
likely  are derived from pre-existing neuroendocrine cells in the biliary epithelium. In this study the 
frequency of neuroendocrine carcinomas was low (3%) and all had intrahepatic metastases. All three 
tumours exhibited strong positive immunostaining for NSE, while positive staining for Cg-A was 
present in >30% cells in 2/3 tumours; they were negative or mostly negative for other markers. 
Positive immunostaining for NSE was present in 10/62 well-differentiated hepatocellular tumours, 
2/17 malignant hepatocellular tumours, ductular structures of 3/3  scirrhous hepatocellular tumours 
and 2/10 cholangiocellular carcinomas. Although this immunoreactivity might indicate 
neuroendocrine differentiation, it may be non-speciﬁc or could be driven by the stromal 
microenvironment, as might occur in scirrhous hepatocellular tumours. The positive staining for Cg-A 
in well differentiated malignant hepatocellular tumours, as well  as in the cholangiolocarcinoma, 
more likely indicates that there is some neuroendocrine differentiation within these tumours, 
particularly since proliferating human HPCs express Cg-A (Roskams et al., 1990, 1991; Turner et al., 
2011). 
  
Conclusions 
 
Histological and immunohistochemical examination of primary hepatic neoplasms in the dog can be 
used to differentiate various hepatocellular and cholangiocellular, as well  as neuroendocrine, 
tumours. The proposed new classiﬁcation in the dog is in accordance with the most recent 
classiﬁcation scheme of primary hepatic neoplasms in humans. This standardised classiﬁcation of the 
primary hepatic neoplasms in the dog could be used as a basis for assessment of therapeutic 
interventions. 
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